Eppin Pharma Inc. of Chapel Hill, North Carolina, is an emerging
pharmaceutical company focused on developing a safe, non-hormonal male
contraceptive taken orally. Our company was founded by Michael G.
O’Rand, PhD, (Inventor, President, and CSO) at the University of North
Carolina at Chapel Hill, Zahed Subhan, PhD, JD (CEO) at Western Carolina
University, and Jeffrey A. Handler, PhD, DABT (COO), a board-certified
toxicologist with broad experience in pharmaceutical and medical device
CEO: Zahed Subhan, Ph.D., MBA, JD, is a Professor of Marketing, Department of
Marketing and Entrepreneurship, College of Business, Western Carolina
University. Dr Subhan has had over 27 years of extensive experience in guiding
pre-clinical and clinical development studies, and gaining regulatory approvals
from FDA and EMEA agencies, as well as experience in executing major
pharmaceutical product launches with multinational companies. Dr Subhan has
also secured seed and venture capital funding for early stage biotechnology
companies as Chief Executive Officer (>$25MM). As Chief Business Officer, Dr
Subhan also contributed to the $100MM IPO (NASDAQ) of a Life Sciences (Genomics)
Company. He has a Ph.D. in Pharmacology from the University of Leeds,
UK, an MBA from the University of Bradford, UK and a JD Law from the University
of London, UK.
President & CSO: Michael O’Rand, Ph.D., is a retired
professor in the Department of Cell Biology and Physiology, University of North
Carolina at Chapel Hill, School of Medicine.
Dr. O’Rand is a reproductive biologist and has more than 35 years of
experience in studying mechanisms underlying human fertilization. Dr. O'Rand established the in vitro fertilization laboratory in UNC School of Medicine’s
North Carolina Memorial Hospital and the first “test tube” baby in North
Carolina. He has 5 issued or pending patents and more than 90 peer-reviewed
publications. He has an A.B. from the University of California at Berkeley, an M.S.
from Oregon State University, Corvallis, Oregon and a Ph.D. in Biology from
Temple University, Philadelphia, PA.
COO: Jeffrey A. Handler, Ph.D., DABT, MBA, is a
Board certified toxicologist with broad experience in many areas of
pharmaceutical and medical device research and development in multiple
therapeutic areas, including antibacterial, therapeutic and aesthetic
dermatology, stroke, Alzheimer’s disease, diabetes, urinary incontinence and
rheumatoid arthritis, obtained over more than 23 years in the pharmaceutical
business. He has extensive leadership and management skills within
pharmaceutical R&D ranging from drug discovery through development and
support of commercialized products and a track record of successful
collaboration with colleagues in both scientific and commercial business areas.
He has a Ph.D. in Pharmacology (1987) from the University of North Carolina at
Chapel Hill and an MBA (2005) from Villanova University, Villanova, PA.
Director of Laboratory Operations: Katherine G. Hamil, is a molecular biologist/biochemist with extensive experience in laboratory management and over 22 years of experience with molecular biology, biochemistry, and tissue culture techniques in the laboratory, with numerous publications in reproductive biology. She has an M.S. and B.S. in biochemistry and cellular and molecular biology from the University of North Carolina at Chapel Hill. NC.
Scientific Advisory Board
The Scientific Advisory Board
(SAB) currently has three members. Dr.
O’Rand, inventor and co-founder of Eppin Pharma, serves as chair of the SAB. The company is currently establishing
relationships with additional accomplished scientists in reproductive biology,
clinical research, and reproductive medicine to serve on Eppin Pharma’s
Scientific Advisory Board. The SAB will
contribute expertise and guidance to Eppin Pharma’s business model and
Scientist and Director, Contraceptive Technology Innovation, FHI360, 359
Blackwell St., Durham, NC 27701 USA
Areas of expertise: Contraceptive
technologies, HIV prevention research, Reproductive health, Hormonal
S. Kopf, PhD
Director, Research & Development, Global Health,
Population & Nutrition, Contraceptive Technology Innovation, FHI360, 359 Blackwell
St., Durham, NC 27701 USA
Reproductive health, Industry experience in women’s health (Wyeth),
Contraceptive technology, reproductive (sperm and testis) biology
John K. Amory MD, MPH
of Medicine, Section Head, General Internal Medicine
of Washington, Seattle WA
Board certified in internal medicine, Men’s reproductive health, Clinical
evaluation of male contraceptives, Reproductive biology